Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

The Battle with Insurance Companies to Obtain Prescriptions

Philip Seo, MD, MHS  |  Issue: March 2018  |  March 17, 2018

The trouble is that Dr. Iinuma denied Mr. Washington’s appeal without having reviewed it. Mr. Washington sued Aetna for “reckless withholding of benefits,” and as part of the lawsuit, Dr. Iinuma was deposed. During the deposition, Dr. Iinuma admitted that he had never reviewed Mr. Washington’s records. He knew this because during his time as the medical director for Aetna, he had not reviewed any patient’s medical records. We apparently should not find this concerning, because he also admitted that he did not know anything about common variable immunodeficiency and did not know the consequences of stopping therapy.

Philip Seo, MD, MHSWith the system we have now, … [w]e learn to overdocument & undertreat, using regimens that we know are doomed to failure, because we must demonstrate that failure to gain access to the drugs that might actually help our patients.

The mind reels. We have all complained—privately and not so—about implacable insurance companies making arbitrary or ill-reasoned decisions, but I wonder how many of us suspected that these decisions were not reasoned at all. And yet, this seems like a natural extension of what we already knew to be true. Of all the times I have received a rejection of preapproval from an insurance company, I wonder how many times the undersigned recognized (or could even spell) granulomatosis with polyangiitis. Treating rheumatic diseases is challenging even for rheumatologists; it is difficult to imagine that every medical director of every insurance company is actually a peer.

Even if Dr. Iinuma had reviewed every page of Mr. Washington’s medical record, it seems doubtful that it would have changed his decision. That possibility was precluded by Dr. Iinuma’s lack of understanding of the patient’s illness and lack of interest in learning about the condition before rejecting a therapy that, by his own admission, he knew nothing about. Dr. Iinuma cannot be the first medical director to sign off on a decision that he was not qualified to make; he was just the first to be caught.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Aetna is now under investigation by California Insurance Commissioner Dave Jones, who told CNN, “If the health insurer is making decisions to deny coverage without a physician actually ever reviewing medical records, that’s of significant concern to me as insurance commissioner in California—and potentially a violation of law.”8

The Way Forward

Mr. Washington had the right idea. If a patient’s insurer makes a decision that seems to lack foundation, it may be time to call for an external referee. Instead of taking the insurance company to court, you may want to start by involving your state’s insurance commission. Truly egregious cases can be referred to your state’s attorney general. Either might help encourage the insurer to do the right thing. Longer term, however, we need more than better enforcement of existing laws; we need better laws.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Page: 1 2 3 4 5 6 7 | Single Page
Share: 

Filed under:Legal UpdatesLegislation & AdvocacyOpinionRheuminationsSpeak Out Rheum Tagged with:drug benefitspharmacy benefit managersprescription

Related Articles

    Marching to the Biosimilar Beat: Questions on Rollout Remain

    September 7, 2023

    The availability of biosimilars for the treatment of patients with rheumatic diseases exploded in 2023. Here’s where we stand and what to expect going forward.

    Possible Impact of Biosimilar Infliximab on U.S. Market in Prescriptions, Pricing

    September 8, 2016

    The use of biosimilars for rheuma­tology in the U.S. became a reality when the U.S. Food and Drug Administration (FDA) approved Inflectra (infliximab-dyyb), a biosimilar to Remicade (infliximab), in April. What this may mean is increased competition among drug companies with regard to pricing and, therefore, potentially lower costs for U.S. patients, according to Seoyoung…

    Biosimilars Debate Heats up over Cost Savings, Safety Concerns

    Biosimilars Debate Heats up over Cost Savings, Safety Concerns

    April 15, 2016

    After years of speculation about potential cost savings and debates on safety, biosimilars are about to step onto the stage of rheumatic disease treatment. On Feb. 9, the Arthritis Advisory Committee of the U.S. Food and Drug Administration (FDA) met in Washington, D.C., and recommended the approval of CT-P13, a proposed biosimilar to infliximab (Remicade),…

    Report on EU’s Experience with Biosimilar Drugs Released: Will U.S. Experience Be Similar?

    October 17, 2017

    As questions about biosimilar medications swirl among U.S. rheumatologists, a recently released report sheds some light on the European experience with biosimilars—and may offer some important insights for the U.S. market. The report, Biosimilars in the EU: Information Guide for Healthcare Professionals, was released in late April by the European Medicines Agency (EMA) and the…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences